Evidence map›Paper›PMID 39286407›Full record

ArticleRespiratory medicine case reports2024

Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy.

Masahiro Yamashita, Hisao Higo, Nobuharu Fujii, Chiaki Matsumoto, Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Masahiro YamashitaDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Hisao HigoDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Nobuharu FujiiDepartment of Hematology and Oncology, Okayama University Hospital, Japan.
Chiaki MatsumotoDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Go MakimotoDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Kiichiro NinomiyaCenter for Comprehensive Genomic Medicine, Okayama University Hospital, Japan.
Masanori FujiiDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Kammei RaiCenter for Innovative Clinical Medicine, Okayama University Hospital, Japan.
Eiki IchiharaCenter for Clinical Oncology, Okayama University Hospital, Japan.
Kadoaki OhashiDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Katsuyuki HottaCenter for Innovative Clinical Medicine, Okayama University Hospital, Japan.
Masahiro TabataCenter for Clinical Oncology, Okayama University Hospital, Japan.
Yoshinobu MaedaDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Nobuaki MiyaharaDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 56-year-old woman who received CD19 chimeric antigen receptor-T cell therapy for refractory diffuse large B-cell lymphoma developed severe coronavirus disease 2019 (COVID-19) and was treated with nirmatrelvir/ritonavir in April 2022. However, she experienced persistent fatigue and cough and fever in June. Computed tomography revealed bilateral ground-glass opacities (GGO), and the patient was treated with corticosteroids for organizing pneumonia after COVID-19. Partial improvement was observed, but new GGO appeared despite corticosteroid therapy. Genome analysis of severe acute respiratory syndrome coronavirus 2 detected Omicron variant BA.1.1.2, which was prevalent at the time of initial infection. The patient was diagnosed with protracted COVID-19 and was treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir, and tixagevimab/cilgavimab. These treatments appeared to contribute to the improvement of protracted COVID-19.

Indexed as

Chimeric antigen receptor-T cell therapyCoronavirus disease 2019Multidrug therapyOrganizing pneumonia

Identifiers

PMID39286407
PMCPMC11404050

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.